Can-Fite BioPharma to Develop a Drug for the Treatment of Sexual Dysfunction

 Can-Fite BioPharma to Develop a Drug for the Treatment of Sexual Dysfunction

Based on reports from clinical trials conducted with other company drugs,
Can-Fite will develop the CF602 drug for the treatment of sexual dysfunction

PR Newswire

PETACH TIKVA, Israel, Nov. 13, 2012

PETACH TIKVA, Israel, Nov. 13, 2012 /PRNewswire/ -- Can-Fite BioPharma (TASE:
CFBI, OTC: CANFY), a biotechnology company with a pipeline of proprietary
small molecule drugs that address inflammatory and cancer diseases, announced
today that it designated the CF602 drug, which was licensed from the Leiden
University, to be developed for the treatment of sexual dysfunction.

During clinical studies conducted with other drugs of the company, patients
suffering from sexual dysfunction reported that they returned to normal
function following the treatment with the company drugs. These findings are
correlated with the company's platform technology, which is targeting the A3
adenosine receptor as a therapeutic target. Adenosine, like NO, is a potent
and short-lived vasorelaxant that functions via cAMP signaling to promote
smooth muscle relaxation. Recent studies show that adenosine functions to
relax the corpus cavernosum and promote penile erection.

The company has filed a patent application for the treatment of sexual
dysfunction utilizing the company drugs, and is planning to develop its 3^rd
pipeline drug, CF602 for this indication. CF602 is a novel A3 adenosine
receptor allosteric modulator enhancing the affinity of the natural ligand
adenosine to its A3 adenosine receptor. The company's scientific team believes
that the unique characteristics of the company drugs including the CF602 drug
make it an applicable drug to be developed for the treatment of sexual
dysfunction.

The erectile dysfunction therapeutic market is estimated to be approximately
$3 billion, and includes mainly the drugs Viagra, Cialis and Levitra.

About Can-Fite Biopharma Ltd.

Can-Fite Biopharma Ltd is an Israeli public company, the ordinary shares of
which are traded on the Tel Aviv Stock Exchange (TASE: CFBI). American
Depository Receipts of the company are traded on the over-the-counter market
(OTC: CANFY). The company, which commenced business activity in 2000, was
founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and
Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent
Attorneys. Pnina Fishman serves as CEO of the company. The company was founded
on the basis of Fishman's scientific findings, and is focused on the
development of small molecule orally bioavailable drugs, ligands to the A3
adenosine receptor. The latter mediates anti-inflammatory and anti-cancer
effects and is suggested as a biological predictive marker. The company's lead
drug, CF101, is in clinical development for the treatment of autoimmune
inflammatory diseases. The CF102 drug candidate is being developed for the
treatment of liver diseases. Can-Fite has a wealth of clinical experience: to
date, more than 700 patients have participated in clinical trials conducted by
the company. Can-Fite previously licensed its activity in the ophthalmic field
to OphthaliX Inc., in which it holds a controlling interest (OTC:OPLI).

Contact:

KCSA Strategic Communications

Jeff Corbin / Phil Carlson

jcorbin@kcsa.com / pcarlson@kcsa.com

212-896-1233

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations
are forward-looking statements, within the meaning of the Private Securities
Litigation Reform Act. The Private Securities Litigation Reform Act of 1995
(PSLRA) implemented several significant substantive changes affecting certain
cases brought under the federal securities laws, including changes related to
pleading, discovery, liability, class representation and awards fees. Since
this information may involve risks and uncertainties and are subject to change
at any time, the Company's actual results may differ materially from expected
results. Additional risks associated with Can-Fite's business can be found in
its periodic filings with the Tel Aviv Stock Exchange.



SOURCE Can-Fite BioPharma

Website: http://www.canfite.com/